#None #Clinical Trials #Pulnovo Medical #EQT Group

Pulnovo Medical Welcomes EQT as New Investor

Pulnovo Medical, a trailblazer in medical devices for pulmonary hypertension and heart failure, has announced a significant milestone by welcoming EQT Group as its new investor. This development comes in light of the recent CE mark certification following the medical device regulations in Europe, which positions Pulnovo for exciting future growth and expansion.

Founded in 2013, Pulnovo has focused on addressing unmet needs in cardiovascular care. It has pioneered a cutting-edge device based on pulmonary artery denervation technology, which not only garnered the designation of an “Innovative Device” by the FDA in 2021 but also received the “Humanitarian Use Device” designation in 2023. The company has been on a remarkable trajectory, recently achieving critical regulatory approvals that will bolster its reach across various markets.

One of the most significant aspects of this investment is the backing from Qiming Venture Partners, which shows a strong vote of confidence in Pulnovo's innovative approach. The latest investment is set to accelerate the company’s global expansion and enhance its capabilities to support international clinical trials and secure regulatory approvals, ultimately aiming to improve treatment options for patients suffering from pulmonary hypertension around the world.

In a statement from Zoe Zhu, director of the EQT Private Capital Asia advisory team, she emphasized the crucial unmet clinical need that exists globally for patients dealing with these severe health issues. The technology developed by Pulnovo is presenting a newfound hope with tangible clinical evidence supporting better outcomes. With EQT’s backing, Pulnovo aims to leverage its extensive expertise in healthcare and life sciences to further its mission of delivering innovative cardiovascular solutions to those who need them most.

Cynthia Chen, the chairwoman of the board and executive chair at Pulnovo Medical, expressed deep gratitude towards EQT and Qiming Venture Partners for their trust and outreach. She noted that Pulnovo is dedicated to meeting the genuine clinical needs through innovative and evidence-based solutions targeted at frontline care. Although transforming clinical innovation into global standard practices comes with its challenges, Pulnovo is committed to bringing relevant medical value to patients worldwide, based on solid scientific principles.

With the CE certification and the reinforcement of its investment foundations, Pulnovo Medical is now better positioned to cater to a worldwide audience suffering from chronic health issues related to pulmonary hypertension. As it embarks on this new phase of growth, the company sets its sights on addressing global health challenges and improving the quality of life for patients who rely on their advanced medical devices.

Conclusion

The partnership between Pulnovo Medical and EQT Group marks a new chapter in the journey of one of the leading innovators in the sphere of medical devices. By focusing on clinical trials and regulatory authorization processes, Pulnovo is not just enhancing its product offerings but also working on establishing itself as a front-runner in the international market for cardiovascular solutions. The next steps for Pulnovo include not only expanding their market presence but also pushing the boundaries of innovation in healthcare technology, making a lasting impact in lives around the globe.